Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities (Details)

v3.20.1
Accrued Liabilities and other Long-Term Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Accrued expenses:    
Professional fees $ 1,153 $ 1,434
Salaries, bonuses and related benefits 6,683 5,843
Research and development 4,215 3,805
Research and development - manufacturing 1,017 826
Research and development - clinical supplies 0 160
Research and development - license maintenance fees 361 519
Research and development - milestones 0 200
Dr. Falk Pharma milestone 0 300
Accrued royalties payable 2,320 1,108
Accrued coupon expense 3,542 838
Other 6,108 1,327
Total accrued expenses 25,399 16,360
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 2,136 5,211
Long-term note payable 77,436 60,425
Total other long-term liabilities 7,126 5,211
Ximino    
Other long-term liabilities:    
Long-term note payable $ 4,990 $ 0